The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis

Engels, C.C.; Kiderlen, M.; Bastiaannet, E.; Eijk, R. van; Mooyaart, A.; Smit, V.T.H.B.M.; ... ; Liefers, G.J. (2016)

Article / Letter to editor

• Breast cancer
• Geriatric oncology
• Epidemiology
• Prognostic markers
• HER-2
• PIK3CA
• Competing risk
• Anti-HER2 therapy

• All authors: Engels, C.C.; Kiderlen, M.; Bastiaannet, E.; Eijk, R. van; Mooyaart, A.; Smit, V.T.H.B.M.; Craen, A.J.M. de; Kuppen, P.J.K.; Kroep, J.R.; Velde, C.J.H. van de; Liefers, G.J.
• Date: 2016-04-30
• Journal: Breast Cancer Research and Treatment
• Volume: 156
• Issue: 2
• Pages: 361 - 370
• DOI: doi:10.1007/s10549-016-3734-y